TauRx Announces Results from Phase 3 Alzheimer's Disease Study, LUCIDITY, Assuring Path for Regulatory Submissions
PR98156
ABERDEEN, Scotland and SINGAPORE, Oct. 6, 2022 /PRNewswire=KYODO JBN/ --
- For people with early Alzheimer's (MCI), HMTM treatment resulted in sustained
improvement in cognition over pre-treatment baseline, and normalisation of
brain atrophy to a rate similar to healthy individuals
- For people with mild to moderate Alzheimer's, HMTM stabilised cognition and
function and reduced rate of brain atrophy compared to historical matched
individuals with AD
- HMTM is an oral drug with a strong safety profile, having no risk of amyloid
related imaging abnormalities
- TauRx will present the Phase 3 findings at the Clinical Trials in Alzheimer's
Disease (CTAD) conference on Wednesday, 30th November 2022, in San Francisco
TauRx Pharmaceuticals Ltd is a global leader in tau-based research in
Alzheimer's disease (AD). Pathological aggregation of Tau correlates with
clinical disease severity and brain atrophy. It is a hallmark of the disease
now generally recognised as an important potential target for treating AD.
Hydromethylthionine mesylate (HMTM) is a potent inhibitor of Tau aggregation
pathology which is taken orally. The Phase 3 LUCIDITY study compared HMTM 16
mg/day with methylthioninium chloride (MTC) given at a dose of 4 mg twice
weekly, the minimum required to prevent bias arising from potential urinary
discolouration. The study was conducted in 598 patients with AD severity
ranging from Mild Cognitive Impairment (MCI) through to the moderate stage of
disease.
TauRx has now completed the first 12-month double-blind phase of the trial. The
second 12-month open label period is ongoing, during which all participants
receive HMTM 16 mg/day. All participants were required to have a positive
amyloid-PET scan and not to be taking standard symptomatic treatments for AD.
Of those receiving MTC 4 mg twice weekly, the majority were unexpectedly found
to have blood levels of active drug above the threshold needed to produce a
clinical effect. In the absence of a true placebo, the trial as designed could
not determine outcomes on primary clinical endpoints relative to a
therapeutically inactive placebo as prespecified. In light of the evidence now
available, TauRx does not believe that a valid blinded placebo-controlled trial
of HMTM with clinical endpoints is technically feasible. TauRx has therefore
analysed the data in terms of the relationship between blood concentration of
drug and treatment effect, change from pre-treatment baseline, and comparisons
against historical controls available from closely matched data from the
Alzheimer's Neuroimaging Initiative (ADNI).
The overall baseline MMSE score was 21 for the study population spanning MCI
through to moderate disease. There was minimal decline over the first 12 months
in participants receiving the 16 mg/day dose on both coprimary cognitive and
functional endpoints (1.3 ADAS-cog11 units and -1.0 ADCS-ADL23 units). The
expected decline over 12 months in an untreated population would be
approximately 5 units on both scales.
In the 105 participants with MCI (baseline MMSE score 23) receiving the 16
mg/day dose, there was statistically significant cognitive improvement of 2
units over the pre-treatment baseline at 6 months (p=0.0002), 12 months
(p=0.0391) and 18 months (p=0.0473) on the ADAS-cog13 scale. The mean change on
the instrumental activities of daily living subscale of ADCS-ADL also remained
above the pre-treatment baseline at 6, 12 and 18 months.
In the 147 participants with mild to moderate AD (baseline MMSE 20) receiving
16 mg/day, there was a 2.5 unit cognitive decline in the first 9 months and no
further decline over the following 9 months. The functional decline on the
ADCS-ADL scale was -2 units at 12 months and -3 units at 18 months representing
a reduction in decline of about 75% relative to a published meta-analysis of
publicly available placebo decline data from historical trials in mild to
moderate AD.
Statistically significant reductions in disease progression as measured by
change in cognitive function (p=0.0008) and brain atrophy (p<0.0001) were
confirmed by comparisons of participants receiving the 16 mg/day dose against
ADNI subjects who were closest to the study population by age and clinical
severity. The differences remained statistically significant in both MCI and AD
subgroups. As expected, LUCIDITY trial participants with MCI entered the study
with more brain atrophy than ADNI healthy aging subjects and consistent with
ADNI MCI subjects. Those treated with HMTM 16 mg/day had a rate of progression
of brain atrophy that was significantly less than in ADNI MCI subjects
(p<0.0001) and comparable to that seen in ADNI healthy aging subjects.
Recent trials that have tested treatments targeting amyloid have been conducted
in comparable or milder populations than the MCI group in the LUCIDITY trial.
When HMTM is compared to publicly available placebo decline data from these
studies as a benchmark, the treatment effects on cognitive and functional
decline are about three-fold larger over 18 months. The benefit seen with HMTM
is clinically meaningful for people with Alzheimer's.
The safety profile seen in LUCIDITY remains strong and consistent with earlier
published HMTM trial data. There were no treatment-related serious adverse
events or evidence of amyloid related imaging abnormalities (ARIA).
On the outcome of the current data analysis, Professor Claude Wischik,
Executive Chairman and co-founder of TauRx, explains, "This is the first time
any treatment has produced evidence of sustained improvement over the
individual's own pre-treatment baseline lasting 18 months at an early
clinically detectable stage of AD, and stabilization of disease progression at
more severe stages. The results in AD confirm published findings from two
earlier HMTM Phase 3 trials. The availability of an accessible oral treatment
which does not require expensive monitoring over routine clinical care opens up
an opportunity to intervene before the onset of the cognitive and functional
decline that lead to loss of independence.
"Tau pathology of the disease is now recognized as an important target for
treatment, and it is encouraging that cognitive improvement is seen at such an
early stage of the disease with a drug targeting Tau. The field has focused
mainly on amyloid as a target for early intervention. Our data are consistent
with the evidence that Tau pathology begins at least 20 years before clinical
symptoms appear and is a viable first-line target for treatment."
To assist with next stages, TauRx has appointed strategic regulatory advisors
in the UK, US and Canada, alongside naming Dr Richard Stefanacci, an
established global key opinion leader in Alzheimer's, as Chief Medical Officer.
Dr Stefanacci is a US-based Internist and fellowship trained Geriatrician who
is an active physician caring for people with Alzheimer's daily.
Dr Stefanacci commented: "These data support our ability to pursue regulatory
submissions. We look forward to making a significant difference addressing this
global unmet need with a medication that is affordable, easy to administer, and
safe. I'm very pleased to be joining the team and supporting the work we're
undertaking to achieve our mission of bringing treatments to people affected by
neurodegenerative diseases caused through protein aggregation – Alzheimer's is
just the beginning."
On the appointment of Dr Stefanacci, Professor Claude Wischik said, "This is an
exciting time for TauRx, and we are very pleased to welcome Dr Stefanacci as
our Chief Medical Officer. His joining the dedicated team at TauRx is testament
to our science and prospects for the future success of the company in helping
to transform the lives of people with Alzheimer's and other neurodegenerative
conditions, as well as the caregivers supporting them."
ABOUT LUCIDITY
LUCIDITY is the only late-stage clinical trial specifically targeting the tau
pathology of Alzheimer's. Aggregation of abnormal tau protein is one of the
hallmark pathologies.
Additional data analysis is ongoing in relation to the 1-year open label phase
of the trial, secondary endpoints including MRI volumetric brain scans, and
exploratory endpoints. A summary of the LUCIDITY study protocol has recently
been published in The Journal of Prevention of Alzheimer's Disease
http://dx.doi.org/10.14283/jpad.2022.63).
ABOUT TAURx PHARMACEUTICALS LTD
The TauRx group of companies was established in 2002 in Singapore, continuing a
partnership with the University of Aberdeen, with primary research facilities
and operation based in Aberdeen, UK. The company has dedicated the past two
decades to developing treatments and diagnostics for Alzheimer's and other
neurodegenerative diseases due to protein aggregation pathology.
Alzheimer's dementia is a leading cause of death throughout the world and one
of the most important public health issues to be addressed globally. TauRx will
contribute to addressing this unmet need with data from LUCIDITY and pursuit of
Medicines and Healthcare products Regulatory Agency (MHRA) approval through the
Innovative Licensing and Access Pathway (ILAP), having been granted an
Innovation Passport, the first stage of the process, in May this year.
TauRx plans to submit HMTM for regulatory approval in the US and Canada in
2023, with other territories to follow, in line with its overall plans to
commercialise HMTM and pursue clinical trials in other related
neurodegenerative diseases.
TAU PATHOLOGY IN ALZHEIMER'S
Through dedicated research programs, it is understood that certain age-related
factors lead to misfolding and aggregation of tau proteins, and the subsequent
formation of tau tangles in Alzheimer's. These tangles disrupt and damage
neuronal function, a process that begins many years before symptoms of dementia
are seen. Tau pathology has been proven to correlate with the clinical decline
(loss of memory and ability to care for oneself) commonly seen in people with
Alzheimer's, establishing it as an important target for treatment. HMTM is a
tau aggregation inhibitor, which effectively crosses the blood brain barrier to
target the source of this damaging process.
https://www.linkedin.com/company/taurx-therapeutics
https://www.youtube.com/user/TauRxTherapeutics
Source: TauRxPharmaceuticals Ltd
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。